Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2003-01-08
2009-10-20
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Reexamination Certificate
active
07604802
ABSTRACT:
A method for producing a cellular immune response in a vertebrate subject comprising administering to the vertebrate subject a vaccine composition comprising a protein particle antigen and a pharmaceutically acceptable excipient is disclosed.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 5709995 (1998-01-01), Chisari et al.
patent: 5851826 (1998-12-01), Fraefel et al.
patent: 5916596 (1999-06-01), Desai et al.
patent: 5928647 (1999-07-01), Rock
patent: 5955342 (1999-09-01), Rovinski et al.
patent: 6086901 (2000-07-01), O'Hagan et al.
patent: 6534064 (2003-03-01), O'Hagan et al.
patent: 6635257 (2003-10-01), Depla et al.
patent: 0339668 (1989-11-01), None
patent: WO 98/50071 (1998-11-01), None
Blanchard et al. Hepatitis C vrus like particle morphogenesis. Journal of Virology, Apr. 2002, vol. 76, No. 8, pp. 4073-4079.
Baumer et al. Hepatitis C virus Structural proteins assemble into viruslike particles in insect cells. Journal of Virology, May 1998, vol. 72, No. 5, 3827-3836.
Eldridge et al. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enchances the level of toxin-neutralizing antibodies. Infectionand Immunity, Sep. 1991, voo. 59, No. 9, 2978-2986.
Kippax, P., Measuring particle size using modern laser diffraction techniques. Paint and Coatings Industry, Aug. 2005.
Tsunoda et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine, Feb. 1999, vol. 17, 675-685.
Speidel et al. Priming of cytotoxic T lymphocytes by five heated aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 1997, vol. 27, 2391-2399.
Tomlinson et al., “Monolithic albumin Particles as Drug Carriers,”Polymers in Controlled Drug DeliveryChapter 3:25-48 (1987).
St. Clair et al., “Crosslinked Protein Crystals for Vaccine Delivery,”Applied Biol. Sciences 96(17):9469-9479 (1999).
Dvorah Diminsky, Reinhold Schirmbeck, Jorge Reimann and Yechezkel Barenholz “Comparison Between Hepatitis B Surface Antigen (HBsAg) Particles Derived from Mammalian Cells (CHO) and Yeast Cells (Hansenula Polymorpha): Composition, Structure and Immunogenicity”,Vaccine,vol. 15, No. 6/7, pp. 637-647, 1997.
Raul Raz, Ron Dagan, Aharon Gallil, Gerta Brill, Imad Kassis and Ronit Koren, “Safety and Immunogenicity of a Novel Mammalian Cell-Derived Recombinant Hepatitis B Vaccine Containing Pre-S1 and Pre-S2 Antigens in Children,”,Vaccine,vol. 14, No. 3, pp. 207-211, 1996.
A.M. Wade-Evans, L. Pullen, C.Hamblin, R. O'Hara, J.N. Burroughs and P.P.C. Mertens, “African Horsesickness Virus VP7 Sub-Unit Vaccine Protects Mice Against a Lethal, Heterologous Serotype Challenge”,Journal of General Virology,(1997), 78, 1611-1616.
St. Clair et al., “Cross-linked Protein Crystals for Vaccine Delivery”, Proc. Natl. Acad. Sci. USA, 1999, vol. 96, No. 17, pp. 9469-9479.
Griffifts et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 1993 67: 3191-3198.
Schirmbeck et al. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 1994 68: 1418-1425.
Ulrich et al. Chimaeric. HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine, 1998, vol. 16. No. 2/3, pp. 272-280.
Tindle et al. Chimeric Hepatitis B Core Antigen Particles Containing B- and Th-Epitopes of Human Papillomavirus Type 16 E7 Protein Induce Specific Antibody and T-Helper Responses in Immunised Mice. Virology, 1994, vol. 200, pp. 547-557.
Gilbert et al. A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnology, 1997, vol. 15, 1280-1284.
Wagner et al. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development. Behring Inst Mitt. 1994 Dec.; (95) : 23-34.
Speidel K. et al., “Priming of cytoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses”, Eur. J. Immunol., vol. 27, 1997, pp. 2391-2399.
Raychaudhuri S. et al., “Fully mobilizing host defense: Building better vaccines”, Nature Biotechnology. vol. 16, Nov. 1999, pp. 1025-1031.
O'Hagan Derek
Singh Manmohan
Bonham David
Gorman Robert
Le Emily M.
Lee Helen
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Method of obtaining cellular immune responses from proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of obtaining cellular immune responses from proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of obtaining cellular immune responses from proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088878